Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Basilea Pharmaceutica AG (BPMUF : OTC)
 
 • Company Description   
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.

Number of Employees: 154

 
 • Price / Volume Information   
Yesterday's Closing Price: $41.00 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 1.09
52 Week High: $51.20
52 Week Low: $41.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 9.57%
12 Week 0.00% 8.50%
Year To Date 0.00% 18.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Grenzacherstrasse 487
-
Basel,V8 4058
CHE
ph: 41-61-606-1111
fax: 41-61-606-1112
investor_relations@basilea.com http://www.basilea.com
 
 • General Corporate Information   
Officers
David Veitch - Chief Executive Officer
Domenico Scala - Chairman
Thomas Werner - Vice-Chairman
Adesh Kaul - Chief Financial Officer
Martin Nicklasson - Director

Peer Information
Basilea Pharmaceutica AG (CORR.)
Basilea Pharmaceutica AG (RSPI)
Basilea Pharmaceutica AG (CGXP)
Basilea Pharmaceutica AG (BGEN)
Basilea Pharmaceutica AG (GTBP)
Basilea Pharmaceutica AG (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: H05131109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: 05/17/22
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 1.09
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/17/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 1.38
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 1.25
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -4.59
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -5.97
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - 1.10
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©